.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
McKinsey
Express Scripts
Medtronic
Daiichi Sankyo
Accenture
Fuji
Mallinckrodt
Moodys
McKesson

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,686,034

« Back to Dashboard

Which drugs does patent 8,686,034 protect, and when does it expire?


Patent 8,686,034 protects HORIZANT and is included in one NDA.

This patent has twenty-six patent family members in twenty-two countries.

Summary for Patent: 8,686,034

Title:Crystalline form of .gamma.-aminobutyric acid analog
Abstract: A crystalline form of a .gamma.-aminobutyric acid analog, and methods of preparing same, are provided.
Inventor(s): Estrada; Tono (Santa Clara, CA), Raillard; Stephen P. (Mountain View, CA), Frauenfelder; Christine (Glis, CH), Zacher; Uwe (Brig, CH)
Assignee: XenoPort, Inc. (Santa Clara, CA)
Application Number:13/164,620
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Arbor Pharms LlcHORIZANTgabapentin enacarbilTABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► Subscribe► SubscribeMANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
Arbor Pharms LlcHORIZANTgabapentin enacarbilTABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
Arbor Pharms LlcHORIZANTgabapentin enacarbilTABLET, EXTENDED RELEASE;ORAL022399-001Apr 6, 2011RXYesYes► Subscribe► Subscribe► SubscribeMANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
Arbor Pharms LlcHORIZANTgabapentin enacarbilTABLET, EXTENDED RELEASE;ORAL022399-001Apr 6, 2011RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,686,034

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,026,279Crystalline form of .gamma.-aminobutyric acid analog► Subscribe
9,150,503Crystalline form of .gamma.-aminobutyric acid analog► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,686,034

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1677767► Subscribe
Singapore147437► Subscribe
Russian Federation2412162► Subscribe
Russian Federation2006116470► Subscribe
Portugal1677767► Subscribe
New Zealand546381► Subscribe
Norway338275► Subscribe
Norway20062112► Subscribe
MexicoPA06004088► Subscribe
South Korea101096480► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Novartis
Covington
Cipla
Johnson and Johnson
Medtronic
Chubb
Mallinckrodt
UBS
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot